NO20081212L - Xantinderivater som selektive HM74A agonister - Google Patents

Xantinderivater som selektive HM74A agonister

Info

Publication number
NO20081212L
NO20081212L NO20081212A NO20081212A NO20081212L NO 20081212 L NO20081212 L NO 20081212L NO 20081212 A NO20081212 A NO 20081212A NO 20081212 A NO20081212 A NO 20081212A NO 20081212 L NO20081212 L NO 20081212L
Authority
NO
Norway
Prior art keywords
xanthine derivatives
hm74a agonists
compounds
selective
derivatives
Prior art date
Application number
NO20081212A
Other languages
English (en)
Norwegian (no)
Inventor
Andrew Mcmurtrie Mason
Ivan Leo Pinto
Jag Paul Heer
John Liddle
Shahzad Sharooq Rahman
Richard Jonathan Daniel Hatley
Ian Edward David Smith
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516464A external-priority patent/GB0516464D0/en
Priority claimed from GB0607736A external-priority patent/GB0607736D0/en
Priority claimed from GB0614569A external-priority patent/GB0614569D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20081212L publication Critical patent/NO20081212L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20081212A 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister NO20081212L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0516464A GB0516464D0 (en) 2005-08-10 2005-08-10 Novel compounds
GB0607736A GB0607736D0 (en) 2006-04-19 2006-04-19 Novel compounds
GB0614569A GB0614569D0 (en) 2006-07-21 2006-07-21 Novel compounds
PCT/EP2006/007869 WO2007017262A1 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists

Publications (1)

Publication Number Publication Date
NO20081212L true NO20081212L (no) 2008-05-06

Family

ID=37189397

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20081212A NO20081212L (no) 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister
NO20081211A NO20081211L (no) 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20081211A NO20081211L (no) 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister

Country Status (29)

Country Link
US (3) US20100179128A1 (el)
EP (3) EP2272848B1 (el)
JP (2) JP5112316B2 (el)
KR (2) KR20080034993A (el)
AR (1) AR055369A1 (el)
AT (1) ATE487719T1 (el)
AU (2) AU2006278216A1 (el)
BR (2) BRPI0615145A2 (el)
CA (2) CA2618963A1 (el)
CR (2) CR9748A (el)
CY (1) CY1111757T1 (el)
DE (1) DE602006018151D1 (el)
DK (1) DK1912991T3 (el)
EA (2) EA200800564A1 (el)
ES (1) ES2401128T3 (el)
HK (1) HK1116779A1 (el)
HR (1) HRP20100725T1 (el)
IL (2) IL189083A0 (el)
MA (2) MA29692B1 (el)
MX (2) MX2008001931A (el)
MY (1) MY142067A (el)
NO (2) NO20081212L (el)
NZ (1) NZ565494A (el)
PE (1) PE20070405A1 (el)
PL (1) PL1912991T3 (el)
PT (1) PT1912991E (el)
SI (1) SI1912991T1 (el)
TW (1) TW200800217A (el)
WO (2) WO2007017261A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
PT1781657E (pt) * 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
SI1912991T1 (sl) * 2005-08-10 2011-03-31 Glaxosmithkline Llc One Franklin Plaza Derivati ksantina kot selektivni hm74a agonisti
CA2656039A1 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
CA2656002A1 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068581A1 (en) 2008-12-08 2010-06-17 Glaxosmithkline Llc Novel compounds
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
PE20130751A1 (es) * 2010-08-16 2013-06-21 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrieno
WO2012040137A1 (en) * 2010-09-23 2012-03-29 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013178572A1 (en) * 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Triazolo compounds as pde10 inhibitors
PE20151779A1 (es) * 2013-03-15 2015-11-20 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas
CA2911926A1 (en) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
US9765089B2 (en) 2013-05-10 2017-09-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
US10208063B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP2994141A4 (en) 2013-05-10 2016-11-23 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
CN104211702B (zh) * 2013-05-29 2018-08-31 中国医学科学院药物研究所 取代黄嘌呤类化合物及其制备方法和用途
CN105646492B (zh) * 2014-11-14 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de) 2016-08-26 2018-03-01 Bihl+Wiedemann Gmbh Diagnose-Repeater für AS-Interface Netze
JP7178357B2 (ja) * 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
WO2023150592A2 (en) * 2022-02-03 2023-08-10 D.E. Shaw Research, Llc N3-substituted uracil compounds as trpa1 inhibitors
WO2024163333A1 (en) * 2023-01-30 2024-08-08 D. E. Shaw Research, Llc Bicyclic imide compounds as trpa1 inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en) 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
JP2753395B2 (ja) 1992-03-04 1998-05-20 セル・セラピューティックス・インコーポレーテッド 鏡像異性体ヒドロキシル化キサンチン化合物
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
EP0746557A4 (en) * 1994-02-18 1997-05-02 Cell Therapeutics Inc INTRACELLULAR SIGNALING MEDIATORS
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6780865B1 (en) * 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
AU4205000A (en) 1999-04-09 2000-11-14 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signaling inhibitors
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
RS50955B (sr) * 2001-02-24 2010-08-31 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Derivati ksantina, njihovo dobijanje i njihova primena kao lekova
WO2002084298A2 (en) 2001-04-11 2002-10-24 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
WO2003004496A1 (en) * 2001-07-03 2003-01-16 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
EP1338595B1 (en) * 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) * 2003-03-11 2005-11-16 张跃 一种吸收式空调主体
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
PT1781657E (pt) * 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
BRPI0517458A (pt) * 2004-10-22 2008-10-07 Smithkline Beecham Corp derivados da xantina com atividade para o receptor hm74a
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20080221108A1 (en) * 2005-02-14 2008-09-11 Richard Hatley Anthranilic Acid Derivatives As Hm74A Receptor Agonists
GB0516462D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
SI1912991T1 (sl) * 2005-08-10 2011-03-31 Glaxosmithkline Llc One Franklin Plaza Derivati ksantina kot selektivni hm74a agonisti
DE102008009758A1 (de) * 2008-02-18 2009-08-20 Beiersdorf Ag Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
WO2010068581A1 (en) 2008-12-08 2010-06-17 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
US20110257205A1 (en) 2011-10-20
WO2007017261A1 (en) 2007-02-15
IL189083A0 (en) 2008-08-07
EP1912992A1 (en) 2008-04-23
NO20081211L (no) 2008-05-08
EA200800564A1 (ru) 2008-08-29
ES2401128T3 (es) 2013-04-17
EA200800555A1 (ru) 2008-08-29
US20100168122A1 (en) 2010-07-01
AU2006278215A1 (en) 2007-02-15
AR055369A1 (es) 2007-08-22
US8143264B2 (en) 2012-03-27
MX2008001929A (es) 2008-03-24
CA2618963A1 (en) 2007-02-15
CA2626723A1 (en) 2007-02-15
MA29692B1 (fr) 2008-08-01
PL1912991T3 (pl) 2011-04-29
EP1912991B1 (en) 2010-11-10
KR20080034993A (ko) 2008-04-22
DE602006018151D1 (de) 2010-12-23
WO2007017262A1 (en) 2007-02-15
EP2272848A1 (en) 2011-01-12
MY142067A (en) 2010-08-30
CR9748A (es) 2008-05-05
BRPI0615145A2 (pt) 2009-11-03
SI1912991T1 (sl) 2011-03-31
PT1912991E (pt) 2011-01-17
JP2009504591A (ja) 2009-02-05
US20100179128A1 (en) 2010-07-15
EP2272848B1 (en) 2012-12-26
HRP20100725T1 (hr) 2011-01-31
PE20070405A1 (es) 2007-05-06
DK1912991T3 (da) 2011-02-21
AU2006278216A1 (en) 2007-02-15
TW200800217A (en) 2008-01-01
JP5112316B2 (ja) 2013-01-09
ATE487719T1 (de) 2010-11-15
HK1116779A1 (en) 2009-01-02
NZ565494A (en) 2011-06-30
MA29693B1 (fr) 2008-08-01
JP2009504592A (ja) 2009-02-05
CY1111757T1 (el) 2015-10-07
EP1912991A1 (en) 2008-04-23
IL189081A0 (en) 2008-08-07
MX2008001931A (es) 2008-03-24
KR20080038396A (ko) 2008-05-06
EA014556B1 (ru) 2010-12-30
CR9749A (es) 2008-05-22
BRPI0614270A2 (pt) 2011-03-22

Similar Documents

Publication Publication Date Title
NO20081212L (no) Xantinderivater som selektive HM74A agonister
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20064584L (no) Tetrahydropyridoindolderivater
TW200606162A (en) Pyrazolopyridine derivatives
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
NO20073719L (no) Kjemiske forbindelser
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20082709L (no) Kjemiske forbindelser
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
NO20061952L (no) Pyrimidin-2-aminderivater og deres anvendelse som A2B-adenosinreseptorantagonister
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
WO2006085113A3 (en) 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists
WO2006096444A3 (en) Chemical compounds
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MX2008001211A (es) Derivados de bencilpiperazina y su uso medico.
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application